Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Classics in Cardiovascular Endocrinology: Aldosterone Action Beyond Electrolytes.

Literature DB >> 26697724

Classics in Cardiovascular Endocrinology: Aldosterone Action Beyond Electrolytes.

Richard J Auchus¹.

Abstract

Entities: Disease

Mesh：

Substances：
Electrolytes
Aldosterone

Year: 2015 PMID： 26697724 PMCID： PMC4733131 DOI： 10.1210/en.2015-2061

Source DB: PubMed Journal: Endocrinology ISSN： 0013-7227 Impact factor: 4.736

× No keyword cloud information.

28 in total

1. The general adaptation syndrome and the diseases of adaptation.

Authors: H SELYE
Journal: J Clin Endocrinol Metab Date: 1946-02 Impact factor: 5.958

2. Renal damage in primary aldosteronism: results of the PAPY Study.

Authors: Gian Paolo Rossi; Giampaolo Bernini; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Massimo Mannelli; Mee-Jung Matterello; Domenico Montemurro; Gaetana Palumbo; Damiano Rizzoni; Ermanno Rossi; Achille Cesare Pessina; Franco Mantero
Journal: Hypertension Date: 2006-06-26 Impact factor: 10.190

3. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245

4. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.

Authors: R Rocha; C T Stier; I Kifor; M R Ochoa-Maya; H G Rennke; G H Williams; G K Adler
Journal: Endocrinology Date: 2000-10 Impact factor: 4.736

5. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism.

Authors: Andrew C Kontak; Zhongyun Wang; Debbie Arbique; Beverley Adams-Huet; Richard J Auchus; Shawna D Nesbitt; Ronald G Victor; Wanpen Vongpatanasin
Journal: J Clin Endocrinol Metab Date: 2010-07-21 Impact factor: 5.958

6. Cardiovascular outcomes in patients with primary aldosteronism after treatment.

Authors: Cristiana Catena; GianLuca Colussi; Elisa Nadalini; Alessandra Chiuch; Sara Baroselli; Roberta Lapenna; Leonardo A Sechi
Journal: Arch Intern Med Date: 2008-01-14

7. Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration?

Authors: Amanda J Rickard; John W Funder; James Morgan; Peter J Fuller; Morag J Young
Journal: Endocrinology Date: 2007-07-19 Impact factor: 4.736

8. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.

Authors: E Born-Frontsberg; M Reincke; L C Rump; S Hahner; S Diederich; R Lorenz; B Allolio; J Seufert; C Schirpenbach; F Beuschlein; M Bidlingmaier; S Endres; M Quinkler
Journal: J Clin Endocrinol Metab Date: 2009-02-03 Impact factor: 5.958

9. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study.

Authors: Xiaoying Ni; Jisheng Zhang; Ping Zhang; Fuquan Wu; Min Xia; Guanghui Ying; Jianghua Chen
Journal: J Clin Hypertens (Greenwich) Date: 2014-07-22 Impact factor: 3.738

10. Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.

Authors: ChongTing Lin; Qing Zhang; HuiFang Zhang; AiXia Lin
Journal: J Clin Hypertens (Greenwich) Date: 2015-07-30 Impact factor: 3.738

4 in total

1. Refining the Definitions of Biochemical and Clinical Cure for Primary Aldosteronism Using the Primary Aldosteronism Surgical Outcome (PASO) Classification System.

Authors: B S Miller; A F Turcu; A T Nanba; D T Hughes; M S Cohen; P G Gauger; R J Auchus
Journal: World J Surg Date: 2018-02 Impact factor: 3.352